The Australian Interstitial Cystitis Therapeutics Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Interstitial cystitis (IC) is a subtype of painful bladder syndrome where specific inflammatory changes in the bladder are present at cystoscopy (a telescope examination of the bladder) with biopsy findings that may include increased numbers of a certain inflammatory cell type (mast cells) in bladder biopsies.
Ninety percent of those who are affected are women. Patients of all ages can be affected, although women in their 20s and 40s are the most typically affected. With IC, these signals get mixed up and then patients feel the need to urinate more often and with smaller volumes of urine than most people. In Australia 1.3 million people are living with IC according to the recent report.
Patients of all ages can be affected, although women in their 20s and 40s are the most typically affected. Studies suggested that females are 9 times more likely to be diagnosed compared to males. Female gender was the only definitive risk factor for developing Interstial Cystitis, this propels the market.
Due to increasing healthcare facilities, a greater number of generic manufacturers presence in market, and an increase in government initiatives, market has growth potential.